Related Experiment Videos
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol
John Wilcox1, Daniel Potter, Marva Moore
1Huntington Reproductive Center, Pasadena, California, USA.
Objective:
To compare the safety and efficacy of single-dose cetrorelix acetate (3 mg) and daily ganirelix acetate (0.25 mg) in the inhibition of premature LH surge in women undergoing cycle-programmed ovarian stimulation before Assisted Reproductive Technology (ART).
Design:
Prospective, open-label, randomized, comparative study.
Setting:
Sixteen ART centers in the United States.
Patient(S):
One hundred eighty-five infertile patients undergoing ART.
Intervention(S):
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm. Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Main Outcome Measure(S):
Percentage of patients who did not have a premature LH surge, defined as LH <10 IU/L on the day of hCG administration. The IVF and embryo transfer (ET) outcomes were assessed.
Result(S):
No patient in either treatment group had a premature LH surge. There were no statistically significant differences between treatments for any IVF/intracytoplasmic sperm injection (ICSI) or ET outcomes, including pregnancy rate (PR). However, cetrorelix required significantly fewer injections than ganirelix. Similar safety profiles were observed.
Conclusion(S):
Cetrorelix and ganirelix effectively prevented LH surges in oral contraceptive (OC) pill-programmed, flexible protocols, with similar safety profiles and PRs; however, cetrorelix required significantly fewer injections, increasing patient convenience.
